Ownership history in CM Management, LLC Β· 17 quarters on record
This page tracks every 13F SEC filing in which CM Management, LLC reported a position in LANTERN PHARMA INC (LTRN). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π CM Management, LLC underperformed the S&P 500 by β33.2% annually on this LTRN position. Timing score: 33% (4/12 decisions correct). Average cost basis: $5.12. Maximum drawdown during holding period: β84.3%.
β Significantly underperformed the S&P 500 by 33.2% ann.
16 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
4 of 12 add/trim decisions correct
Best entry: $3.19 (2024 Q4) Β· Worst: $19.25 (2020 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
11 adds Β· 1 trim. Bought during 6 of 10 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.57% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size